Immune Checkpoint Inhibitor-Related Hypophysitis: A Call for Vigilance.
作者信息
Lee Ju Hee
机构信息
Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
出版信息
Endocrinol Metab (Seoul). 2025 Jun;40(3):391-393. doi: 10.3803/EnM.2025.2477. Epub 2025 Jun 24.
Abstract
摘要
相似文献
1
Immune Checkpoint Inhibitor-Related Hypophysitis: A Call for Vigilance.
Endocrinol Metab (Seoul). 2025 Jun;40(3):391-393. doi: 10.3803/EnM.2025.2477. Epub 2025 Jun 24.
2
MRI Findings of Immune Checkpoint Inhibitor-Induced Hypophysitis: Possible Association with Fibrosis.
AJNR Am J Neuroradiol. 2020 Sep;41(9):1683-1689. doi: 10.3174/ajnr.A6692. Epub 2020 Aug 6.
3
Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces.
Expert Opin Biol Ther. 2021 Aug;21(8):1097-1120. doi: 10.1080/14712598.2021.1869211. Epub 2021 Apr 1.
4
A Novel Etiology of Hypophysitis: Immune Checkpoint Inhibitors.
Endocrinol Metab Clin North Am. 2020 Sep;49(3):387-399. doi: 10.1016/j.ecl.2020.05.002. Epub 2020 Jul 15.
5
Exploring a Rarity: Incidence of and Therapeutic Approaches for Neurological Complications and Hypophysitis in Cancer Patients on Immune Checkpoint Inhibitors-A Single-Center Study.
Curr Oncol. 2023 Dec 18;30(12):10509-10518. doi: 10.3390/curroncol30120766.
6
Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
J Immunother Cancer. 2019 Sep 12;7(1):248. doi: 10.1186/s40425-019-0729-3.
7
Late-onset recurrent immune checkpoint inhibitor-related pneumonitis after cessation of pembrolizumab: a case report.
Immunotherapy. 2025 Apr;17(5):317-320. doi: 10.1080/1750743X.2025.2488609. Epub 2025 Apr 2.
8
Magnetic resonance imaging criteria of immune checkpoint inhibitor-induced hypophysitis.
Curr Probl Cancer. 2021 Feb;45(1):100644. doi: 10.1016/j.currproblcancer.2020.100644. Epub 2020 Aug 29.
9
Elevated CK from immune checkpoint inhibitor- related hypophysitis: a case report.
J Chemother. 2025 Jul;37(4):372-375. doi: 10.1080/1120009X.2024.2359838. Epub 2024 May 31.
10
Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome.
Cancer Immunol Immunother. 2021 Dec;70(12):3669-3677. doi: 10.1007/s00262-021-02955-y. Epub 2021 May 11.
本文引用的文献
1
Combined PD-1 and CTLA-4 Blockade Increases the Risks of Multiple Pituitary Hormone Deficiency and Isolated Adrenocorticotropic Deficiency: A Prospective Study.
Endocrinol Metab (Seoul). 2025 Jun;40(3):459-468. doi: 10.3803/EnM.2024.2180. Epub 2025 Feb 11.
2
Clinical outcomes of endocrine and other disorders induced by immune checkpoint inhibitors in Japanese patients.
Sci Rep. 2025 Jan 2;15(1):390. doi: 10.1038/s41598-024-84488-9.
3
Incidence of Endocrine-Related Dysfunction in Patients Treated with New Immune Checkpoint Inhibitors: A Meta-Analysis and Comprehensive Review.
Endocrinol Metab (Seoul). 2023 Dec;38(6):750-759. doi: 10.3803/EnM.2023.1785. Epub 2023 Nov 13.
4
Immune-related adverse events of immune checkpoint inhibitors: a review.
Front Immunol. 2023 May 25;14:1167975. doi: 10.3389/fimmu.2023.1167975. eCollection 2023.
5
Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival.
J Natl Compr Canc Netw. 2023 Feb 24;21(3):281-287. doi: 10.6004/jnccn.2022.7098.
6
Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society.
Endocrinol Metab (Seoul). 2022 Dec;37(6):839-850. doi: 10.3803/EnM.2022.1627. Epub 2022 Dec 26.
7
Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline.
Eur J Endocrinol. 2022 Oct 25;187(6):G1-G21. doi: 10.1530/EJE-22-0689. Print 2022 Dec 1.
8
Hypophysitis: An update on the novel forms, diagnosis and management of disorders of pituitary inflammation.
Best Pract Res Clin Endocrinol Metab. 2019 Dec;33(6):101371. doi: 10.1016/j.beem.2019.101371. Epub 2019 Dec 12.
9
Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society.
Endocr J. 2019 Jul 28;66(7):581-586. doi: 10.1507/endocrj.EJ19-0163. Epub 2019 Jun 25.
10
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580. doi: 10.1038/s41571-019-0218-0.
Zotero 插件